XOMA Ltd. 8K - 11/30/06
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): November 30, 2006
(Exact
name of registrant as specified in its charter)
(State
or
other jurisdiction of incorporation)
|
0-14710
|
|
52-2154066
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
| |
|
|
|
2910
Seventh Street, Berkeley, California
|
|
94710
|
|
(Address
of principal executive offices)
|
|
(Zip
code)
|
| |
|
|
|
Registrant's
telephone number, including area code
|
|
(510)
204-7200
|
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
1.01.
Entry
into a Material Definitive Agreement
XOMA
has
amended its 2002 cross-license agreement with Dyax Corp. Under the 2002
agreement, XOMA received a license to Dyax’s “Ladner” patents, which are
relevant to certain aspects of practicing antibody phage display technology,
and
a license to use one of Dyax’s original antibody phage display libraries. In
addition, XOMA is entitled to receive royalty payments for the use of XOMA’s
antibody expression technology by Dyax or its collaborators. Under the
amendment, XOMA also receives limited quantities of certain biological materials
that will allow it to perform several selections using Dyax’s current generation
antibody phage display library for the discovery, development and
commercialization of therapeutic antibodies independently and with XOMA’s
co-development partners.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated:
December 5,
2006
XOMA
LTD.
By:
/s/ Christopher
J. Margolin
Christopher
J. Margolin
Vice
President, General
Counsel
and Secretary